Complement deposition assays and a murine lower limb deep vein thrombosis model were used to investigate the role of MUC4 mutation in thrombotic risk and explore the underlying mechanism involving terminal complement activation in PNH patients. This evidence concerns the gene MUC4 and deep vein thrombosis.